Dr. J - do you have an opinion on the lipid-friendly AI, aromasin (exemestane)? versus something like, letrozole or armidex used concurrently with HRT/TRT.
Thanks for clearing that up Dr. John. I was debating between Aromasin and Arimidex as some people like Glen favor it but I think I will go with Adex as there seems to be more info on it.
If you don't mind, Id appreciate if you could evaluate my proposed cycle:
Proposed First Injectible Cycle - Critique
I read your articles and I have based my HCG/PCT on them.
OK. Well thanks a lot for all your contibutions Dr. John. It is greatly appreciated!
Damn...and I was just getting ready to jump!
glad we made something of this thread. Aromasin is good stuff imo.
How many times do you people need to be told.Originally Posted by MattHines
http://anabolicminds.com/forum/male-...ideration.htmlYou are banned for 1 week effective immediately.I will make this very clear one more time. Do not come into this forum and ask for any assitance of any kind whatesoever on how to run any portion of your steroid cycles.
I believe I have made myself very clear. I will very aggressively enforce any future indiscretions.
"He will turn the hearts of the fathers to their children, and the hearts of the children to their fathers"
Eh, what's up Doc?
In your opinion, would you consider Letrozole stronger than Exemestane, due to its ability to block aromatase in adipose tissue? I've never read anything on Exemestane having this ability, besides Letro is prescribed for certain estrogen-related cancer treatments..
Not that I've ever used letro, mind you..
I personally decimate my libido with Letro use. Even at a paltry .25mg ED, my libido suffers. It's quite potent as we know.
Now I can take upwards of 25mg of Exemestane/day and not get the same libido quelling effects.
For that reason alone, I feel it is better. We all know that we don't want to completely eradicate estrogen regardless.
I did not know about Letro having the advantage of aromatase inhibition in adipose... well there is a lot I don't know regardless.
Interesting thread, would like to see more of a discussion here about this. It affects many of us. I was lead to believe many of the things superchicken has stated.
I was just responding to what BigPeteFox said in regards to AI in adipose.
I completely agree with your statement on the advice being thrown around. Some speak on subjects that they have no real world experience with.
I only have my own experience to fall back on, which of course are not controlled nor do I have hard data to reference.
true, in addition, I suppose real world experience can also be construed as actually studying the compounds in question.
Thanks for your input as always Doc.
I've read many places the same information as this..Originally Posted by Dr. John
Biology of aromatase inhibitors: pharmacology/endocrinology within the breast -- Miller 6 (2): 187 -- Endocrine-Related Cancer
Biology of aromatase inhibitors: pharmacology/endocrinology within the breast
Both mammary adipose tissue and breast cancers have the ability to aromatize androgens into oestrogens. Such potential may maintain the growth of hormone-dependent tumours. It has therefore been important to determine the effects of new aromatase inhibitors such as formestane, exemestane, anastrozole and letrozole on oestrogen biosynthesis and concentrations of endogenous hormones within the breast. Studies based on in vitro incubations of breast cancer and cultures of mammary adipose tissue fibroblasts demonstrate that these drugs are highly effective inhibitors, with IC50 values ranging between 1 and 50 nM (although the relative efficacy varies between tissues and test systems). Despite this potential, in vitro incubations of breast tissues from patients treated with type II inhibitors such as aminoglutethimide and letrozole can display paradoxically high aromatase activity; this appears to be caused by the reversible nature of the inhibition, coupled with induction/stabilization of the aromatase enzyme. To assess in situ effects within the breast, postmenopausal women with large primary breast cancers have been treated neoadjuvantly with aromatase inhibitors using a protocol that included (i) breast biopsy before treatment, (ii) definitive surgery after 3 months of treatment and (iii) infusion of [3H]androstenedione and [14C]oestrone in the 18 h immediately before biopsy and surgery. With this study design, it has been shown that drugs such as letrozole profoundly inhibit in situ aromatase activity and reduce endogenous oestrogens within the breast.
Here's a .pdf of the product Femara, it states the adipose issue in the description..